about
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-bas...
Read More
3.65
-0.18
(-4.70%)
3.3M
XNAS Volume
XNAS 30 Jul, 2025 5:30 PM (EDT)
Board Meeting
The next board meeting for Altimmune Inc is on 08 Aug 2025 for the purpose of Altimmune Inc Second Quarter Earnings Results for 2025
See details
Not Eligible
Expensive Valuation
Technically Bearish
Altimmune Inc Live Price Chart
Switch to TradingView
Loading Fundamental data..
Loading data..